Janux Therapeutics, Inc.

NASDAQ:JANX

56.83 (USD) • At close December 20, 2024
Bedrijfsnaam Janux Therapeutics, Inc.
Symbool JANX
Munteenheid USD
Prijs 56.83
Beurswaarde 3,284,745,585
Dividendpercentage 0%
52-weken bereik 7.79 - 71.71
Industrie Biotechnology
Sector Healthcare
CEO Dr. David Alan Campbell Ph.D.
Website https://www.januxrx.com

An error occurred while fetching data.

Over Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface

Vergelijkbare Aandelen

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

4.91 USD

Seer, Inc. logo

Seer, Inc.

SEER

2.31 USD

Ocugen, Inc. logo

Ocugen, Inc.

OCGN

0.774 USD

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

5.35 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

4.24 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

4.97 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

19.83 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)